Active ingredientGanirelixCat. No. P-G017-001CAS 124904-93-4Family · Pharmaceutical analytical standards
Ganirelix
A GnRH antagonist, a synthetic decapeptide approved in the United States in 1999 and in the European Union in 2000: in assisted reproduction it prevents premature ovulation during ovarian stimulation. This family brings together the active ingredient and other impurities.
Did you know?Compared with the natural GnRH it derives from, six of its ten amino acids are substituted, and it binds the receptor about nine times more tightly than the original hormone.
Go to the active ingredient →Active ingredientGanirelixCat. No. P-G017-001CAS 124904-93-4
Active ingredientGanirelix acetateCat. No. P-G017-002CAS 129311-55-3
ImpurityFmoc-D-Har(Et)2-OHCat. No. P-G017-003CAS 1386327-10-1
ImpurityFmoc-harg(ET)2-OHCat. No. P-G017-004CAS 1386327-04-3
ImpurityGanirelix Acetate Impurity BCat. No. P-G017-005CAS 2135326-92-8
ImpurityGanirelix Impurity 1Cat. No. P-G017-008
ImpurityGanirelix Impurity 2Cat. No. P-G017-011
ImpurityGanirelix Impurity 3Cat. No. P-G017-012
ImpurityGanirelix Impurity 4Cat. No. P-G017-013
ImpurityGanirelix Impurity ACat. No. P-G017-016
ImpurityGanirelix Impurity BCat. No. P-G017-017
ImpurityGanirelix Impurity CCat. No. P-G017-018
ImpurityGanirelix Impurity FCat. No. P-G017-021CAS 129225-22-5
ImpurityGanirelix Impurity F TFA SaltCat. No. P-G017-022No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.